Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-κB activity in PC-3 human prostate cancer cells

Wei,Xingchuan; Du,Zhi-Yun; Cui,Xiao-Xing; Verano,Michael; Mo,Rong Qing; Tang,Zhi Kai; Conney,Allan H.; Zheng,Xi; Zhang,Kun

doi:10.3892/ol.2012.710

Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-κB activity in PC-3 human prostate cancer cells

Authors:
- Xingchuan Wei
- Zhi-Yun Du
- Xiao-Xing Cui
- Michael Verano
- Rong Qing Mo
- Zhi Kai Tang
- Allan H. Conney
- Xi Zheng
- Kun Zhang
View Affiliations

Affiliations: Department of Chemistry and Chemical Engineering, Guangzhou University, Guangzhou 510006, P.R. China, Laboratory of Natural Medicinal Chemistry and Green Chemistry, College of Light Industry and Chemical Engineering, Guangdong University of Technology, Guangzhou 510006, P.R. China, Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA, Allan H. Conney Laboratory for Anticancer Research, Guangdong University of Technology, Guangzhou 510006, P.R. China
Published online on: May 10, 2012 https://doi.org/10.3892/ol.2012.710
Pages: 279-284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Curcumin is a non-nutritive yellow pigment found in the spice turmeric, which is derived from the rhizome of the plant Curcuma longa Linn. Six cyclohexanone analogues of curcumin (A1-A6) were investigated for their effects on growth and apoptosis in PC-3 human prostate cancer cells. The ability of these compounds to inhibit NF-κB activity in PC-3 cells was also determined. Five out of the six curcumin analogues (A2-A6) had stronger inhibitory effects compared to curcumin on the growth of cultured PC-3 cells. Compounds A2-A6 also had stronger stimulatory effects on apoptosis in PC-3 cells than curcumin, and these curcumin analogues more potently inhibited NF-κB activity than curcumin. The inhibitory effects of these compounds on NF-κB activity correlated with their effects on growth inhibition and apoptosis stimulation in PC-3 cells. The results of the present study provide a rationale for in vivo studies with A2-A6 using suitable animal models of prostate cancer.

View Figures

View References

1	Lao CD: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 6:102006. View Article : Google Scholar : PubMed/NCBI
2	Goel A, Kunnumakkara AB and Aggarwal BB: Curcumin as ‘Curecumin’: from kitchen to clinic. Biochem Pharmacol. 75:787–809. 2008.
3	Aggarwal BB and Sung B: Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 30:85–94. 2009. View Article : Google Scholar : PubMed/NCBI
4	Moragoda L, Jaszewski R and Majumdar AP: Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 21:873–878. 2001.PubMed/NCBI
5	Anto RJ, Mukhopadhyay A, Denning K and Aggarwal BB: Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis. 23:143–150. 2002. View Article : Google Scholar
6	Squires MS, Hudson EA, Howells L, Sale S, Houghton CE, Jones JL, Fox LH, Dickens M, Prigent SA and Manson MM: Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol–3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol. 65:361–376. 2003.PubMed/NCBI
7	Hanif R, Qiao L, Shiff SJ and Rigas B: Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med. 130:576–584. 1997. View Article : Google Scholar
8	Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P and Aggarwal BB: Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 20:7597–7609. 2001. View Article : Google Scholar : PubMed/NCBI
9	Piantino CB, Salvadori FA, Ayres PP, Kato RB, Srougi V, Leite KR and Srougi M: An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines. Int Braz J Urol. 35:354–360. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hilchie AL, Furlong SJ, Sutton K, Richardson A, Robichaud MR, Giacomantonio CA, Ridgway ND and Hoskin DW: Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria. Nutr Cancer. 62:379–389. 2010. View Article : Google Scholar
11	Teiten MH, Gaascht F, Eifes S, Dicato M and Diederich M: Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 5:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
12	Cabrespine-Faugeras A, Bayet-Robert M, Bay JO, Chollet P and Barthomeuf C: Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Nutr Cancer. 62:148–153. 2010. View Article : Google Scholar : PubMed/NCBI
13	Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, Hama T, Masuda H and Horie S: Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate. 70:1127–1133. 2010. View Article : Google Scholar : PubMed/NCBI
14	Khor TO, Keum YS, Lin W, Kim JH, Hu R, Shen G, Xu C, Gopalakrishnan A, Reddy B, Zheng X, Conney AH and Kong AN: Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res. 66:613–621. 2006. View Article : Google Scholar : PubMed/NCBI
15	Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI
16	Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB and Sood AK: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 13:3423–3430. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 67:3853–3861. 2007. View Article : Google Scholar
18	Sun ZJ, Chen G, Zhang W, Hu X, Liu Y, Zhou Q, Zhu LX and Zhao YF: Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma. Mol Pharmacol. 79:106–118. 2011.PubMed/NCBI
19	Jutooru I, Chadalapaka G, Lei P and Safe S: Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem. 285:25332–25344. 2010. View Article : Google Scholar : PubMed/NCBI
20	Guo H, Yu JH, Chen K and Ye ZQ: Curcumin induced the expression of inhibitor kappaBalpha protein in human prostate cancer cells. Zhonghua Wai Ke Za Zhi. 44:1256–1259. 2006.PubMed/NCBI
21	Anand P, Sundaram C, Jhurani S, Kunnumakkara AB and Aggarwal BB: Curcumin and cancer: an ‘old-age’ disease with an ‘age-old’ solution. Cancer Lett. 267:133–164. 2008.
22	Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 14:4491–4499. 2008. View Article : Google Scholar : PubMed/NCBI
23	Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21:2895–2900. 2001.PubMed/NCBI
24	Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY and Lin JK: Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 15:1867–1876. 1997. View Article : Google Scholar : PubMed/NCBI
25	Tomren MA, Másson M, Loftsson T and Tønnesen HH: Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin. Int J Pharm. 338:27–34. 2007.PubMed/NCBI
26	Grogan G: Emergent mechanistic diversity of enzyme-catalysed beta-diketone cleavage. Biochem J. 388:721–730. 2005. View Article : Google Scholar : PubMed/NCBI
27	Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J, Zhao Y, Li X and Yang S: Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem. 17:2623–2631. 2009. View Article : Google Scholar : PubMed/NCBI
28	Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA and Rosengren RJ: Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Invest New Drugs. 29:87–97. 2011. View Article : Google Scholar
29	Yadav B, Taurin S, Rosengren RJ, Schumacher M, Diederich M, Somers-Edgar TJ and Larsen L: Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. Bioorg Med Chem. 18:6701–6707. 2010. View Article : Google Scholar : PubMed/NCBI
30	Du ZY, Bao YD, Liu Z, Qiao W, Ma L, Huang ZS, Gu LQ and Chan AS: Curcumin analogs as potent aldose reductase inhibitors. Arch Pharm (Weinheim). 339:123–128. 2006. View Article : Google Scholar : PubMed/NCBI
31	Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS and Conney AH: Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res. 13:5480–5487. 2007. View Article : Google Scholar : PubMed/NCBI
32	Ploszaj T, Motyl T, Orzechowski A, Zimowska W, Wareski P, Skierski J and Zwierzchowski L: Antiapoptotic action of prolactin is associated with up-regulation of Bcl-2 and down-regulation of Bax in HC11 mouse mammary epithelial cells. Apoptosis. 3:295–304. 1998. View Article : Google Scholar : PubMed/NCBI
33	Zheng X, Chang RL, Cui XX, Avila GE, Lee S, Lu YP, Lou YR, Shih WJ, Lin Y, Reuhl K, Newmark H, Rabson A and Conney AH: Inhibitory effect of12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res. 64:1811–1820. 2004. View Article : Google Scholar : PubMed/NCBI
34	Romero-Weaver AL, Wang HW, Steen HC, Scarzello AJ, Hall VL, Sheikh F, Donnelly RP and Gamero AM: Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2. Mol Cancer Res. 8:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
35	Zheng X, Chang RL, Cui XX, Avila G, Huang MT, Liu Y, Kong AN, Rabson AB and Conney AH: Inhibition of NF-κB by (E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY11-7082; BAY) is associated with enhanced 12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and apoptosis in human prostate cancer PC-3 cells. Int J Oncol. 32:257–264. 2008.
36	Chen A and Zheng S: Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-κB and ERK signalling. Br J Pharmacol. 153:557–567. 2008.PubMed/NCBI
37	Li L, Aggarwal BB, Shishodia S, Abbruzzese J and Kurzrock R: Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer. 101:2351–2362. 2004.
38	Aggarwal BB: Nuclear factor-κB: the enemy within. Cancer Cell. 6:203–208. 2004.
39	Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR and Schäfer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003. View Article : Google Scholar : PubMed/NCBI
40	Holley AK, Xu Y, St Clair DK and St Clair WH: RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Ann NY Acad Sci. 1201:129–136. 2010. View Article : Google Scholar : PubMed/NCBI
41	Karin M: NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 1:a0001412009.
42	Royuela M, Rodríguez-Berriguete G, Fraile B and Paniagua R: TNF-α/IL-1/NF-κB transduction pathway in human cancer prostate. Histol Histopathol. 23:1279–1290. 2008.
43	Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F and de la Taille A: The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol. 25:477–489. 2007.
44	Flynn V Jr, Ramanitharan A, Moparty K, Davis R, Sikka S, Agrawal KC and Abdel-Mageed AB: Adenovirus-mediated inhibition of NF-κB confers chemo-sensitization and apoptosis in prostate cancer cells. Int J Oncol. 23:317–323. 2003.
45	Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES and Wang MB: Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway. Clin Cancer Res. 14:6228–6236. 2008.PubMed/NCBI
46	Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, Wang CY, Shoji M, Sun A, Snyder JP, Liotta D and Fu H: Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol. 74:654–661. 2008. View Article : Google Scholar : PubMed/NCBI